DDAVP Drug Patent Profile

When do Ddavp patents expire, and what generic alternatives are available?

Ddavp is a drug marketed by Ferring Pharms Inc and is included in three NDAs.

The generic ingredient in DDAVP is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ddavp

A generic version of DDAVP was approved as desmopressin acetate by MEITHEAL on October 15^th, 1997.

Summary for DDAVP

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	39
Patent Applications:	2,836
Drug Prices:	Drug price information for DDAVP
What excipients (inactive ingredients) are in DDAVP?	DDAVP excipients list
DailyMed Link:	DDAVP at DailyMed

See drug prices for DDAVP

Pharmacology for DDAVP

Drug Class	Factor VIII Activator Vasopressin Analog
Physiological Effect	Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration

US Patents and Regulatory Information for DDAVP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring Pharms Inc	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938-001	Mar 30, 1984	AP	RX	Yes	Yes
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996		DISCN	Yes	No
Ferring Pharms Inc	DDAVP	desmopressin acetate	SPRAY, METERED;NASAL	017922-002	Feb 6, 1989		DISCN	Yes	No

Expired US Patents for DDAVP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring Pharms Inc	DDAVP	desmopressin acetate	SPRAY, METERED;NASAL	017922-002	Feb 6, 1989	5,500,413
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-001	Sep 6, 1995	7,022,340
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-002	Sep 6, 1995	7,022,340

International Patents for DDAVP

See the table below for patents covering DDAVP around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0163723	DDAVP ANTIDIURETIC AND METHOD THEREFOR
Portugal	1500390
Italy	1056718	PROCESSO PER LA PRODUZIONE DI UN POLIPEPTIDE AD AZIONE ANTIDIURETICA

Supplementary Protection Certificates for DDAVP

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3225249	CA 2019 00023	Denmark		PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
3225249	2019C/520	Belgium		PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622	122017000006	Germany		PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504

DDAVP Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for DDAVP (Desmopressin)

Introduction to DDAVP (Desmopressin)

DDAVP, or desmopressin, is a synthetic analogue of the natural hormone vasopressin. It is widely used for its antidiuretic and hemostatic properties, treating conditions such as diabetes insipidus, nocturnal enuresis, and certain bleeding disorders like hemophilia A and von Willebrand disease.

Market Size and Growth

The global desmopressin market has been experiencing significant growth and is projected to continue this trend in the coming years. As of 2022, the market was valued at approximately USD 1.055 billion and is expected to grow to USD 1.657 billion by 2030, with a Compound Annual Growth Rate (CAGR) of around 5.8% during the forecast period[1][3].

Drivers of Market Growth

Increasing Prevalence of Diabetes Insipidus and Nocturnal Enuresis

The rising incidence of diabetes insipidus and nocturnal enuresis is a major driver of the desmopressin market. As awareness of these conditions increases, more patients are seeking diagnosis and treatment, thereby driving the demand for desmopressin[3].

Growing Awareness of Effective Treatment Options

Increased awareness and adoption of clinical drugs for these conditions have led to favorable outcomes, contributing to the market's growth. This includes both counseling sessions and drug treatments, which are becoming more widely accepted[1].

Advancements in Drug Formulations

Advancements in drug formulations and delivery methods, such as sustained-release formulations and more convenient administration routes (e.g., nasal sprays and injectable solutions), are enhancing patient adherence and satisfaction. These improvements are expected to further boost the market[3].

Expanding Indications for Bleeding Disorders

Desmopressin's role in treating bleeding disorders, particularly in patients with hemophilia and von Willebrand disease, is expanding. Its efficacy in enhancing hemostasis before surgical procedures or during bleeding episodes is increasing its adoption among healthcare providers[3].

Market Segments

Forms of Desmopressin

Desmopressin is available in various forms, including injectable solutions, nasal sprays, and tablets. Each form has its own advantages and is suited to different patient needs and conditions. For instance, injectable forms are often used for immediate antidiuretic and hemostatic effects, while nasal sprays are more convenient for long-term management[1].

Applications

The drug is used in both pediatric and geriatric populations. In pediatric use, it is commonly prescribed for nocturnal enuresis and diabetes insipidus, while in geriatric use, it is often used for managing diabetes insipidus and other age-related conditions[1].

End-Users

The primary end-users of desmopressin include hospitals, homecare settings, specialty clinics, and other healthcare facilities. The drug's administration and monitoring often require professional healthcare settings, although homecare use is also common, especially for chronic conditions[1].

Distribution Channels

Desmopressin is distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The ease of access through these channels has contributed to the drug's widespread adoption[1].

Financial Trajectory

Current Market Value

As of 2022, the global desmopressin market was valued at USD 1.055 billion. This valuation reflects the drug's established presence and growing demand in the healthcare market[1].

Projected Growth

The market is projected to grow to USD 1.657 billion by 2030, with a CAGR of 5.8% during the forecast period. This growth is driven by the increasing prevalence of treated conditions, advancements in drug formulations, and expanding indications for use[1][3].

Regional Market Analysis

The desmopressin market is analyzed across various geographic regions, including the USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Each region has its own growth trajectory, influenced by local healthcare policies, patient demographics, and market dynamics[3].

Challenges and Opportunities

Challenges

One of the significant challenges faced by the desmopressin market is the availability of generic products. For instance, the suspension of Ferring Pharmaceuticals' nasal spray product, STIMATE®, due to packaging issues, led to a gap in the market that was partially filled by generic alternatives from 503B outsourcing facilities like STAQ Pharma[4].

Opportunities

The increasing investments by several market players in research and development are creating opportunities for innovation and expansion. The development of new delivery systems and the exploration of additional therapeutic uses for desmopressin are expected to drive further growth in the market[1].

Regulatory Framework

Desmopressin is subject to various regulatory frameworks, particularly in the context of its manufacturing, distribution, and use. For example, the FDA's oversight of 503B outsourcing facilities ensures that generic products meet safety and efficacy standards[4].

Patient Epidemiology and Pipeline Analysis

The patient epidemiology for conditions treated with desmopressin, such as diabetes insipidus and bleeding disorders, is critical for understanding market demand. Pipeline analysis indicates ongoing research into new formulations and therapeutic uses, which will likely influence future market growth[1].

Pricing Analysis

The pricing of desmopressin can vary based on the form of the drug, the distribution channel, and the geographic region. The availability of generic products has introduced pricing competition, which can affect the overall market dynamics[4].

Expert Analysis and Market Scenario

Experts in the field highlight the importance of desmopressin in managing various medical conditions. The market scenario is characterized by a balance between established players and emerging generic competitors, with a focus on innovation and patient-centric care[3].

Key Takeaways

• Market Growth: The desmopressin market is expected to grow from USD 1.055 billion in 2022 to USD 1.657 billion by 2030, with a CAGR of 5.8%.
• Drivers: Increasing prevalence of diabetes insipidus and nocturnal enuresis, growing awareness of effective treatment options, and advancements in drug formulations.
• Market Segments: Various forms (injectable, nasal spray, tablets), applications (pediatric and geriatric), and end-users (hospitals, homecare, specialty clinics).
• Challenges: Availability of generic products and regulatory compliance.
• Opportunities: Increasing investments in R&D and expanding indications for use.

FAQs

What is the projected market size of the desmopressin market by 2030?

The desmopressin market is projected to reach USD 1.657 billion by 2030[1].

What is the CAGR of the desmopressin market from 2023 to 2030?

The CAGR of the desmopressin market is expected to be around 5.8% from 2023 to 2030[1].

What are the primary drivers of the desmopressin market growth?

The primary drivers include the increasing prevalence of diabetes insipidus and nocturnal enuresis, growing awareness of effective treatment options, and advancements in drug formulations[3].

Which forms of desmopressin are commonly used?

Desmopressin is commonly available in injectable solutions, nasal sprays, and tablets[1].

What are the key end-users of desmopressin?

The key end-users include hospitals, homecare settings, specialty clinics, and other healthcare facilities[1].

Sources

1. Data Bridge Market Research: Global Desmopressin Market Size, Outlook, Trends, Report | Forecast 2030
2. Sanofi U.S.: DDAVP Injection (desmopressin acetate)
3. Research and Markets: Desmopressin - Global Strategic Business Report
4. National Hemophilia Foundation: Latest Updates on Generic Desmopressin Product
5. Business Research Insights: Desmopressin Market Size, Trends, Outlook, Forecast, 2032